Tango Therapeutics Stops Development of USP1 Inhibitor After Liver Toxicity Issues
Tango Therapeutics Stops Development of USP1 Inhibitor After Liver Toxicity Issues
Tango Therapeutics 在出現肝毒性問題後停止了 USP1 抑制劑的開發
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊